O-2545

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by EdChem (talk | contribs) at 10:12, 2 August 2016 (italicise and unit spacing). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

O-2545
Legal status
Legal status
  • In general: unscheduled
Identifiers
  • (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol
CAS Number
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H36N2O2
Molar mass408.575 g/mol g·mol−1
3D model (JSmol)
  • CC1=CC[C@H]2[C@@](Oc3c(c(cc(c3)C(CCCCn4cncc4)(C)C)O)[C@@H]2C1)(C)C
  • InChI=1S/C26H36N2O2/c1-18-8-9-21-20(14-18)24-22(29)15-19(16-23(24)30-26(21,4)5)25(2,3)10-6-7-12-28-13-11-27-17-28/h8,11,13,15-17,20-21,29H,6-7,9-10,12,14H2,1-5H3/t20-,21-/m1/s1 ☒N
  • Key:RZGSWWCABDVBGX-NHCUHLMSSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both CB1 and CB2 receptors, with Ki values of 1.5 nM at CB1 and 0.32 nM at CB2.[1]


See also

References

  1. ^ Martin BR, et al. Pharmacological characterization of novel water-soluble cannabinoids. Journal of Pharmacology and Experimental Therapeutics. 2006 Sep;318(3):1230-9. PMID 16757541